- Previous Close
28.29 - Open
28.50 - Bid 26.98 x --
- Ask 27.50 x --
- Day's Range
26.55 - 28.84 - 52 Week Range
19.00 - 36.05 - Volume
3,996 - Avg. Volume
8,993 - Market Cap (intraday)
1.362B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-4.54 - Earnings Date Feb 11, 2025 - Feb 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 16, 2022
- 1y Target Est
--
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
lasalabs.com77
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: LASA.BO
View MorePerformance Overview: LASA.BO
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LASA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LASA.BO
View MoreValuation Measures
Market Cap
1.36B
Enterprise Value
1.55B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.14
Price/Book (mrq)
1.50
Enterprise Value/Revenue
1.30
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.65%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.05B
Net Income Avi to Common (ttm)
-195.13M
Diluted EPS (ttm)
-4.54
Balance Sheet and Cash Flow
Total Cash (mrq)
14.96M
Total Debt/Equity (mrq)
22.83%
Levered Free Cash Flow (ttm)
--